Toxicity Due to Radiotherapy

3

Review clinical trials related to Toxicity Due to Radiotherapy. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression

Stereotactic Ablative Radiotherapy (SABR) is a modern RT technique that delivers high doses of radiation to small tumor targets using highly conformal techniques, while trying to avoid healthy tissues and organs. However, SABR treatment requires increased planning, treatment time, cost and potential for higher toxicity due to the higher dose. The purpose of this study is to compare single fraction (SF) SABR vs. multiple fraction (MF) SABR in regards to toxicities, progression-free survival, quality of life (QoL), and cost-effectiveness. In a subset of patients, we will also compare patient QoL, hospitalization rates, and cost-effectiveness between patients who complete QoL questionnaires, record symptoms and receive healthcare provider-guided intervention vs. patients who complete QoL questionnaires only.

Participants needed: 598
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Robert OlsonUpdated: Jun 25, 2026Locations: 14
Eligibility criteria

1-5 current oligometastatic or oligo-progressive lesions [+17]

Uncontrolled concurrent malignant cancer [+16]

Status: Recruiting

Hypofraction Radiotherapy for Locally Advanced Non-small Cell Lung Cancer

Definitive concurrent chemoradiotherapy followed by durvalumab (Pacific protocol) has been the standard modality for stage III locally advanced non-small cell lung cancer. In spite of the median overall survival of 47.5 months, there still existed 38.5% and 6.9% patients who finally developed intra-thorax and extra-thorax recurrence respectively in long-term follow-up. The relatively low local control rate has been the bottleneck for further improvement of overall survival. Hypofraction radiotherapy has been validated to be able to increase the local control rate in two prospective trials. Therefore, this trial is designed to explore the safety and primary efficacy of hypofraction radiotherapy followed by immune checkpoint inhibitors for stage III locally advanced non-small cell lung cancer.

Participants needed: 36
Trial details
Phase: Phase 1, Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Anhui Provincial HospitalUpdated: Jun 25, 2024Locations: 1
Eligibility criteria

18-70 years old; [+6]

Younger than 18 years old or older than 70 years old; [+6]

Status: Recruiting

Impact of Gonadotoxic Therapies on Fertility

The goal of this observational study is to learn how gonadotoxic treatments (chemotherapies, radiotherapies or immunotherapies) affect the fertility status of participants with cancer. The main questions it aims to answer are: * in females, if cancer therapies reduce the Anti-Müllerian hormone (AMH) concentration (ovarian reserve); * in males, if cancer therapies reduce sperm concentration (sperm quality).

Participants needed: 7,000
Trial details
Age: 14-50Biological sex: AllType: ObservationalSponsor: Michael von WolffUpdated: Jun 3, 2024Locations: 1Duration: 10 Years
Eligibility criteria

Patients with cancer or with benign reasons undergoing chemotherapy and/or radio... [+3]

Missing consent; [+1]